285
Participants
Start Date
February 28, 2010
Primary Completion Date
October 31, 2012
Study Completion Date
October 31, 2012
BMS-650032
Tablets, Oral, 200 mg, Twice Daily, 48 weeks
BMS-650032
Tablets, Oral, 200 mg, Twice Daily, 12 or 24 weeks, depending on response
Placebo
Tablets, Oral, 0 mg, twice daily, 48 weeks
Placebo
Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12
Placebo
Tablets, Oral, 0 mg, twice daily 24 weeks
Peginterferon Alfa-2a
Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks
Peginterferon Alfa-2a
Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 24 or 48 weeks, depending on response
Ribavirin
Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks
Ribavirin
Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 24 or 48 weeks depending on response
Local Institution, Prov. Buenos Aires
Local Institution, Prov de Santa Fe
Local Institution, Torino
James J Peters Vamc, The Bronx
Local Institution, Marseille
Hospital Of The University Of Pennsylvania, Philadelphia
Mercy Medical Center, Baltimore
Metropolitan Research, Fairfax
University Of North Carolina, Chapel Hill, Chapel Hill
Local Institution, Madrid
Local Institution, Málaga
Florida Hospital Transplant Center, Orlando
Local Instituition, Montpellier
Alabama Liver & Digestive Specialists (Alds), Montgomery
Gastro One, Germantown
Local Institution, Valencia
Dean Clinic, Madison
Local Institution, Vandœuvre-lès-Nancy
Local Institution, Mainz
Local Institution, Frankfurt
Local Institution, Heidelberg
Local Institution, Paris
Local Institution, Paris
Local Institution, Créteil
Local Institution, Würzburg
Oregon Health Science Univ, Portland
University Of Alabama At Birmingham, Birmingham
The Research Institute, Springfield
Umass Memorial Medical Center, Worcester
Healthcare Research Consultants, Tulsa
Local Institution, Buenos Aires
Local Institution, Ciudad de Buenos Aires
Local Institution, Dublin
Local Institution, Alicante
Local Institution, Barcelona
Local Institution, London
Local Institution, London
Local Institution, London
Local Institution, Manchester
Local Institution, Glasgow
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY